Modified hemoglobin-based blood substitutes: crosslinked, recombinant and encapsulated hemoglobin

Area of Science:

• Biomedical Engineering
• Hematology
• Biochemistry

Background:

• Native hemoglobin requires modification for use as a blood substitute due to limitations.
• First-generation molecularly modified hemoglobins are advancing through clinical trials, including Phase III.

Purpose of the Study:

• To review the development and generations of hemoglobin-based blood substitutes.
• To highlight advancements in modifying hemoglobin for improved efficacy and safety.

Main Methods:

• Review of molecular modification techniques for hemoglobin, including crosslinking and conjugation.
• Discussion of encapsulation strategies for creating artificial red blood cells.
• Overview of recombinant hemoglobin production.

Main Results:

• First-generation hemoglobin blood substitutes are in late-stage clinical trials.
• Second-generation systems involve enzyme conjugation (e.g., hemoglobin-superoxide dismutase-catalase).
• Third-generation approaches focus on microencapsulated hemoglobin, mimicking natural red blood cells.

Conclusions:

• Hemoglobin modification and encapsulation are key to developing effective blood substitutes.
• Ongoing research progresses through distinct generations, aiming for improved functionality and biocompatibility.
• Artificial red blood cells represent a promising future direction for hemoglobin-based oxygen carriers.